KRAS mutations in non‑small cell lung cancer and options of treatment

02/2020

MUDr. Marie Drösslerová; MUDr. Libor Havel

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

SUMMARY

KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations are the most frequently oncogene aberrations in non-small cell lung cancer (NSCLC). KRAS-mutated NSCLC represents a heterogeneous subgroup because there are different KRAS subtypes, mutations and comutations. It results in different biological behavior of the tumor and its response to treatment. A large majority of patients with KRAS mutations have short-term survival. Trials for targeted treatment have failed. Immunotherapy is the most promising treatment for some patients with KRAS-mutated NSCLC. A very hopeful is an experimental cancer drug AMG 510 which is tested in phase 1/2 clinical trial.

Key words

non-small cell lung cancer, KRAS mutation, targeted therapy